EVIDENCE IN ACTION

CASE STUDIES

OUR WORK

FROM INSIGHT TO ACTION.

Explore how we help healthcare businesses understand markets, assess opportunities and shape strategy.

Our case studies show the challenge, our approach and how the evidence informed business decisions.

Market Sizing & Growth Strategy

SELECT A CASE STUDY

Nine European countries | 295 oncologists | 1,060 patient records

The challenge: How can a company quantify patient populations and treatment opportunities across different breast cancer markets?

Our approach: FMR conducted two waves of quantitative oncologist research with patient record collection and desk research. The work examined HR+/HER2- and triple-negative breast cancer, disease stages, treatment lines, mutations and patient characteristics.

Business implications: Country-level patient and treatment evidence enabled comparison of market opportunities and informed geographic prioritisation and commercial planning.

Nine countries | 48 stakeholder interviews

The challenge: Where are patients diagnosed and treated, which centres influence care, and what growth opportunities exist in a rare disease market?

Our approach: FMR combined desk research and stakeholder interviews with KOLs, healthcare professionals and hospital stakeholders to investigate prevalence estimates, diagnosis and treatment, specialist centres and patient flows.

Business implications: Mapped treatment centres and patient pathways, clarified stakeholder influence and highlighted potential opportunities for future engagement and market growth.

France | 56 physicians | 333 patient cases

The challenge: Which patient profiles might be considered for a new antiretroviral treatment and what market potential could it have?

Our approach: FMR combined telephone and online physician research with case exercises involving 333 previously treated patients. The study examined treatment pathways, preferences, eligible patient profiles and potential switches from established therapies.

Business implications: Provided evidence for opportunity sizing, patient eligibility estimates, potential treatment gain and loss and positioning considerations.

Seven countries | Qualitative and quantitative phases

The challenge: Which countries, customer groups and purchasing channels offer the best opportunities for introducing a laboratory product?

Our approach: FMR interviewed and surveyed laboratory users and purchasing stakeholders in Singapore, Thailand, Malaysia, Saudi Arabia, South Africa, Turkey and Israel. The research assessed market size, brands, purchase criteria, competing products and buying channels.

Business implications: Provided market and competitive evidence to inform country prioritisation, product requirements, channel planning and launch pricing considerations.

France | 15 qualitative and 50 quantitative oncologist interviews

The challenge: What patient groups and treatment situations may offer the strongest opportunity for a proposed antiemetic treatment?

Our approach: FMR conducted 15 in-depth oncologist interviews and a quantitative survey with 50 oncologists to examine treatment algorithms, existing therapies, patient eligibility and potential switching.

Business implications: Provided evidence on eligible patient profiles, potential uptake and where the new offer might be positioned relative to current treatments.

Launch & Commercialization Strategy

SELECT A CASE STUDY

France | 5 KOLs, 2 patient associations and 2 payer-side stakeholders

The challenge: How should a new hereditary ATTR amyloidosis treatment enter a complex rare disease market?

Our approach: FMR combined desk research and in-depth interviews to explore reference centres, patient flows, market access, stakeholder interactions and pre-launch priorities.

Business implications: Clarified launch success factors and provided evidence to inform a proposed go-to-market plan, including stakeholder engagement and commercialization priorities.

France | 48 workshop participants and 220 survey physicians

The challenge: Which patients and prescribers should be prioritised for a new type 2 diabetes treatment?

Our approach: Twelve projective workshops and a quantitative survey assessed patient profiles, treatment choices, perceived benefits and early adoption barriers.

Business implications: Identified actionable patient profiles and evidence to inform prescriber engagement, positioning and launch communications.

Germany, France, Spain, Italy and UK | 30 specialist interviews

The challenge: Where could a new cholangiocarcinoma product fit in the patient journey?

Our approach: FMR interviewed specialists involved in CCA care to map diagnosis and treatment decisions, patient-journey milestones, stakeholders and unmet needs.

Business implications: Clarified potential entry points in the care pathway and evidence relevant to launch positioning and stakeholder engagement.

France | 25 hospital and clinical stakeholder interviews

The challenge: How should a new CT contrast injector system and business model be introduced to hospitals?

Our approach: FMR interviewed biomedical engineers, radiologists, radiographers, buyers and healthcare leaders about procurement decisions, competing solutions and product expectation